Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (50)	7/30/1999 9:08:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 447

Somewhere in one of Peter's biotech something or other threads, I suggested that we would start to see M&A based on patent portfolios. I specifically pointed to OSIP and SIBI. From what I've seen, it hasn't happened, even apart from OSIP and SIBI..... i.e., no interest thus far in "a SNAP", either. This one is interesting, in that it's Pfizer's major biotech partner in cancer, teaming with PNU. Pfizer already has a license to everything (IP) that OSIP owns. So..... it sort of looks like Pfizer will look the other way for this one? Compare to SIBI. There's NBIX news too.